https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24679 Wed 17 Nov 2021 16:32:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43462 P<.001). Higher non-GI somatic symptom scores were significantly associated with both symptom transitions (odds ratio, 3.9; 95% CI, 1.38 to 10.77) and having sustained symptoms (odds ratio, 12.7; 95% CI, 4.62 to 34.90). Conclusion: The overall population prevalence of chronic unexplained GI symptoms is stable, but in individuals, transitions seem to be the rule. As these various GI syndromes appear to be so intimately interconnected, the common underlying pathogenesis may account for a major subgroup of chronic unexplained GI disorders.]]> Tue 20 Sep 2022 08:49:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36112 Thu 06 Feb 2020 14:32:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36111 Thu 06 Feb 2020 14:25:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12777 Sat 24 Mar 2018 08:18:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12778 Sat 24 Mar 2018 08:18:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12398 1cm with intestinal metaplasia) and IMGEJ (intestinal metaplasia in biopsies from the gastroesophageal junction) from 1976 to 2006 in Olmsted County, MN, were identified using Rochester Epidemiology Project resources. Demographic and clinical data were abstracted from medical records and pathology confirmed by gastrointestinal pathologists. The association of baseline characteristics with overall and progression-free survival was assessed using proportional hazards regression models. Outcome measures were baseline characteristics and overall survival of subjects with IMGEJ compared to those with BE. Results: In all, 487 patients (401 with BE and 86 with IMGEJ) were identified and followed for a median interval of 7 (BE subjects) to 8 (IMGEJ subjects) years. Subjects with BE were older, heavier, reported reflux symptoms more often, and had higher prevalence of advanced neoplasia than those with IMGEJ. No patient with IMGEJ progressed to esophageal adenocarcinoma (EAC) in contrast to BE subjects who had a cumulative risk of progression of 7% at 10 years and increased risk of death from EAC (standardized mortality ratio 9.62). The overall survival of subjects with BE and IMGEJ did not differ from that expected in similar age- and sex-distributed white Minnesota populations. Conclusions: Subjects with IMGEJ appear to have distinct clinical characteristics and substantially lower cancer progression risk compared to those with BE.]]> Sat 24 Mar 2018 08:15:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19964 Sat 24 Mar 2018 07:58:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17801 50 years to assess awareness regarding BE, willingness to participate in screening, and preferences regarding method of screening. Methods evaluated were sedated endoscopy (sEGD), unsedated transnasal endoscopy (uTNE) and video capsule (VCE). Results: A total of 136 from 413 (33 %) adults responded [47 % males, mean (SD) age 63 (10.2) years], and 26 % of responders knew of BE at baseline. After reading the information on BE, 72 % were interested in screening. A history of undergoing screening tests and GI symptoms were predictive of interest. Unsedated techniques were preferred by 64 % (VCE: 56 % and uTNE: 8 %) versus sEGD (36 %). Conclusions: The majority of adults were willing to undergo screening for BE/EAC, with a preference for unsedated techniques.]]> Sat 24 Mar 2018 07:57:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27609 3-fold more likely to report adequate relief than those given placebo (odds ratio = 3.1; 95% confidence interval: 1.1-9.0). Neither amitriptyline nor escitalopram appeared to affect GE or meal-induced satiety after the 10-week period in any group. Subjects with delayed GE were less likely to report adequate relief than subjects with normal GE (odds ratio = 0.4; 95% confidence interval: 0.2-0.8). Both antidepressants improved overall quality of life. Conclusions Amitriptyline, but not escitalopram, appears to benefit some patients with FD, particularly those with ulcer-like (painful) FD. Patients with delayed GE do not respond to these drugs.]]> Sat 24 Mar 2018 07:39:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27168 Sat 24 Mar 2018 07:31:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27822 Sat 24 Mar 2018 07:31:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27248 Sat 24 Mar 2018 07:29:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22752 Sat 24 Mar 2018 07:14:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21659 Mon 11 Mar 2019 12:16:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47763 P = 0.008). Compared with placebo, the overall IBS BSS severity score was lower in the pregabalin arm (26 vs 42, P = 0.009). Differences were observed for the diarrhoea‐BSS and bloating‐BSS scores (P = 0.049 and 0.016, respectively). No differences between groups were seen for constipation‐BSS scores. Adequate relief was not different between the two arms (46% vs 36%, P = 0.35). 63% pregabalin vs 45% placebo had a change in pain score ≥30 at week 12 from baseline (P = 0.10). Post‐treatment IBS‐QoL scores did not differ between groups. Conclusion: This trial suggests that pregabalin may be beneficial for IBS abdominal pain, bloating and diarrhoea.]]> Fri 27 Jan 2023 11:07:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34107 T CC genotype has been previously linked to FD and TT genotype to antidepressant response in depression. The ss genotype of the 5-HTT LPR variant of the serotonin transporter gene (SLC6A4) has been linked to selective serotonin reuptake inhibitor (SSRI) response. We aimed to examine whether GNβ3 825C>T and 5-HTT LPR polymorphisms result in differential treatment effects in FD patients receiving antidepressant therapy. Methods: Participants were randomized to receive placebo, 50 mg AMI, or 10 mg escitalopram (ESC). The primary end point was adequate relief for ≥5 weeks of the last 10 weeks. Genotyping of GNβ3 825C>T and 5-HTT LPR was performed utilizing PCR-based methods. Results: GNβ3 825C>T and 5-HTT LPR genotype data were available for 256 (88%) and 246 (84%) patients, respectively. Both polymorphisms were in Hardy-Weinberg equilibrium. In tests for differential treatment, neither 5-HTT LPR nor GNβ3 825C>T genotype influenced response to therapy (P=0.89 and P=0.54, respectively). Although there was a tendency for a more favorable response to ESC in the SS/LS genotype compared to the LL genotype groups (40% vs. 31% reporting adequate relief of FD symptoms) among those in the ESC treatment arm, this was not significant (P=0.43). Conclusions: GNβ3 825C>T and 5-HTT LPR genetic variants do not alter treatment response to tricyclic and SSRI antidepressants in FD.]]> Fri 08 Feb 2019 10:43:58 AEDT ]]>